{"nctId":"NCT01305655","briefTitle":"Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL","startDateStruct":{"date":"2008-07"},"conditions":["Acute Lymphoblastic Leukemia (ALL)"],"count":47,"armGroups":[{"label":"Glucarpidase arm","type":"EXPERIMENTAL","interventionNames":["Drug: Glucarpidase"]}],"interventions":[{"name":"Glucarpidase","otherNames":["VORAXAZEÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nChildren and adolescents who experience delayed MTX-clearance and renal dysfunction during high-dose methotrexate treatment in NOPHO ALL-2008.\n\nExclusion Criteria:\n\nChildren and adolescents with earlier anaphylactic reaction to Glucarpidase. Pregnant patients.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity, Mucositis, MTX Elimination Time and Permanent Kidney Damage.","description":"Glucarpidase was used in case of predefined toxic MTX values at defined time points and/or in combination with decreased renal function.\n\nA total of 47 patients of the 1286 ALL-patients included in the protocol (3.7 %) were treated with Glucarpidase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":[]}}}